Skip to main content
MedPathMedPath Home
Clinical Trials/jRCT2033250787
jRCT2033250787
Recruiting
Not Applicable

A Non-Interventional Study (NIS) PASS to characterize secondary malignancies of T-cell origin following tisagenlecleucel therapy

Not provided0 sites30 target enrollmentStarted: TBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSecondary Malignancies of T-cell Origin

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
30
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
No limit to No limit (—)
Sex
All

Inclusion Criteria

  • •Study participants eligible for inclusion in this study must meet all of the following criteria:
  • •Prior use of tisagenlecleucel treatment in CTL019 clinical trial setting or post-marketing/commercial tisagenlecleucel setting as outlined for Cohort 1 and Cohort 2
  • •Confirmed diagnosis of secondary malignancy of T-cell origin via redacted pathology report and/or clinical confirmation by the Principal Investigator/clinician responsible for enrolling the participant. Clinical judgement may be required in cases where the diagnosis is not clearly confirmed in the redacted pathology report. There also may be cases in certain site/countries, where sharing the redacted pathology reports is not allowed, hence the clinical diagnosis will be allowed for eligibility.
  • •Availability of existing secondary malignancy of T cell origin specimen(s) from tissue, and/or bone marrow aspirate sample(s) and/or blood or DNA extracted from blood (with confirmed T-cell malignancy diagnosis in the sample provided) collected during routine standard of care during the secondary malignancy of T-cell origin diagnosis. Often, only a limited amount of the appropriate sample(s) may be available. For the testing process, a specimen containing the malignant T-cells for the secondary malignancy of T-cell origin must be present. The type of specimen/sample for testing is determined based on the location of the secondary malignancy of T-cell origin. For example, bone marrow aspirate and/or blood and/or bone marrow biopsy may be needed for analysis for a secondary malignancy of T cell origin when the malignant T cells are present in blood and/or bone marrow, and tissue such as a lymph node location or cutaneous or other location is needed when this is the region of the body affected by the secondary malignancy of T-cell origin. Blood, (even if NOT involved with the T cell malignant cells) when available, may also be used for comparison to the tissue/bone marrow used for the analysis. Novartis has established ranges of CAR transgene level in blood for all 3 pivotal trial indications at specific time points. This is used for comparison.
  • •See laboratory manual for detailed instructions. The following types of samples are recommended for collection if available/pre-existing:
  • •a. Tumor tissue (FFPE block (ambient temp), unstained slides (ambient temp), or bone marrow aspirate in EDTA or blood in EDTA and frozen, if malignant T-cells present)
  • •b. Peripheral blood EDTA frozen- to be used when available and either not involved with T-cell malignancy for comparison to the tumor sample provided and/or if peripheral blood has circulating malignant T cells for analysis.
  • •c. Bone marrow aspirate EDTA frozen if involved with secondary malignancy of T-cell origin.
  • •d. DNA extracted from blood or bone marrow aspirate stored frozen
  • •e. Bone marrow biopsy if malignant T-cells are present (FFPE block, unstained slides, ambient temperature)

Exclusion Criteria

  • •Study participants meeting any of the following criteria are not eligible for inclusion in this study:
  • •Ongoing enrollment on Novartis sponsored CTL019 interventional or LTFU clinical trial
  • •Cases where there is no existing available specimens that include the secondary malignancy of T cell origin (tumor tissue and/or existing blood and/or bone marrow and/or DNA from blood for testing)
  • •Cases where informed consent is not possible.

Investigators

Sponsor
Not provided

Similar Trials

Recruiting
Not Applicable
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
NCT07378969Novartis Pharmaceuticals30
Recruiting
Phase 1/2
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression
2022-501822-39-00Philogen S.p.A.113
Completed
Phase 1
A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.
2023-506661-65-00Bristol-Myers Squibb Services Unlimited Company40
Not yet recruiting
Not Applicable
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (J2A-MC-GZPR)Peripheral Arterial Disease
jRCT20312505701,205
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies
2024-511453-22-00Kumquat Biosciences Inc.112